These case studies are just some examples of how, at Mewburn Ellis, we work with our clients to help them obtain, enforce and exploit intellectual property rights to achieve their commercial objectives
Mewburn Ellis helped entrepreneurial start-up Wadaro protect its unique software, which allows mobile network operators to measure the performance of their networks.
When the UK Border Agency detained an RSS Edge Shoes shipment, the company turned to Mewburn Ellis for help.
When our client, a major international engineering company, wanted to purchase a small UK company in order to access its technology in hydraulic power take-off from offshore wind turbines, they turned to Mewburn Ellis for advice.
Mewburn Ellis has recently helped Box Steam Brewery to devise an IP strategy to help protect and develop their trade mark portfolio as the company increases its exposure in the market place.
PT20 was invented in the UK at the Medical Research Council (MRC)'s Human Nutrition Research laboratory in Cambridge.
Zealand Pharma is a biotechnology company based in Copenhagen, Denmark. It specialises in the discovery, design and development of novel peptide medicines.
In recent years Mewburn Ellis has successfully helped TASER International, Inc prevent the registration of the mark TAZER by a third party at the European Union Intellectual Property Office (EUIPO).
Mewburn Ellis has worked closely with Haydale Graphene Industries plc, and its wholly owned subsidiary Haydale Limited, (together “Haydale”) on patent and trade mark protection, commercial intellectual property (IP) advice, as well as playing a major role in the IP due diligence for its £6.6 million Initial Public Offering (IPO) on AIM.
Aquaporin is globally recognised for its unique, highly innovative membrane systems for water purification and power generation. Mewburn Ellis has been working for Aquaporin since 2007. Over the years we have helped them to secure a multi-jurisdiction patent portfolio.
Midatech Pharma is a nanomedicine company focused on the development and commercialisation of multiple high-value, targeted therapies for major diseases with unmet therapeutic needs.
Only by safeguarding the IP of its unique product range can EcoTechnilin reap the deserved commercial benefits of its innovations.
Mewburn Ellis is proud that WIPO-IPOS has recognised WisTa’s “relentless efforts” in commercialising neurodegenerative treatments
Mewburn Ellis acted on behalf of a saddlery company in a complex legal dispute over who owned the trade mark ReactorPanel.
Our clients, who work in the field of automotive safety equipment, had a steering wheel airbag product which they wanted to market. They were concerned about a European patent granted to one of their two largest competitors and wanted to oppose it.
Richard Clegg, a Mewburn Ellis partner in the life sciences patent team, started working on aptamer/SELEX technology in 2003 and prosecuted the original patents relating to this technology in Europe.